Suchergebnisse - "Vandebosch, An"

PubPharm (63)

41

Improving interim decisions in randomized trials by exploiting information on short‐term endpoints and prognostic baseline covariates

enthalten in: Pharmaceutical Statistics | 2020

von Van Lancker, K. | Vandebosch, A. | Vansteelandt, S.

42

Evaluating futility of a binary clinical endpoint using early read-outs

enthalten in: Statistics in medicine | 2019

von Van Lancker, K. | Vandebosch, A. | Vansteelandt, S. | +1

43

Evaluating futility of a binary clinical endpoint using early read‐outs

enthalten in: Statistics in Medicine | 2019

von Van Lancker, K. | Vandebosch, A. | Vansteelandt, S. | +1

44

Evaluation of six months sputum culture conversion as a surrogate endpoint in a multidrug resistant-tuberculosis trial

enthalten in: PloS one | 2018

von Meyvisch, P. | Kambili, C. | Andries, K. | +7

45

Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845

enthalten in: Virology journal | 2017

von Vijgen, L. | Thys, K. | Vandebosch, A. | +3

46

Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845

enthalten in: Virology journal | 2017

von Vijgen, L. | Thys, K. | Vandebosch, A. | +3

47

Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845

enthalten in: Virology journal | 2017

von Vijgen, L. | Thys, K. | Vandebosch, A. | +3

48

Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection

enthalten in: BMC gastroenterology | 2017

von Bourgeois, S. | Van Vlierberghe, H. | Moreno, C. | +15

49

Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection

enthalten in: BMC gastroenterology | 2017

von Bourgeois, S. | Van Vlierberghe, H. | Moreno, C. | +15

50

Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection

enthalten in: BMC gastroenterology | 2017

von Bourgeois, S. | Van Vlierberghe, H. | Moreno, C. | +15